Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiotherapy plus temozolomide for newly diagnosed adult supratentorial IDH-mutant CDKN2A/B-deleted grade 2/3 astrocytoma
ChiCTR2300068649Phase 2Recruiting
- Sponsor
- Beijing Tiantan Hospital
- Start
- Feb 2023
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of temozolomide in astrocytoma and glioma, sponsored by Beijing Tiantan Hospital. Primary endpoint: Overall survival. Started Feb 2023; status: recruiting.
02
Drugs
temozolomide
03
Conditions
astrocytomaglioma
Beyond the preview
Go deeper on ChiCTR2300068649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300068649.